Porcine Circovirus Diseases: Current Insights and Future Strategies for Effective Control, with a Focus on Porcine Circovirus 2 (PCV2)

Abstract

Porcine Circovirus Associated Disease (PCVAD), caused by Porcine Circovirus Type 2 (PCV2), is a major health concern in swine production, leading to significant economic losses. The diagnosis of PCVAD relies on a combination of clinical signs and confirmatory laboratory techniques. Clinically, affected pigs exhibit weight loss, jaundice, poor growth, respiratory distress, and gastrointestinal issues. Histopathological examination reveals characteristic lesions such as lymphoid depletion, granulomatous inflammation, and the presence of inclusion bodies in lymphoid tissues. Immunohistochemistry (IHC) and in situ hybridization (ISH) are critical for detecting PCV2 antigens and viral nucleic acids in tissue samples, respectively. Molecular diagnostic methods, including PCR and quantitative PCR (qPCR), offer rapid and precise detection of PCV2 DNA, with advancements like digital droplet PCR (ddPCR) improving sensitivity. Serological tests, such as immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA), are useful for detecting PCV2 antibodies, aiding in assessing infection status and immune response. Genotyping assays help track the evolution of PCV2 strains, essential for understanding epidemiology and vaccine development. Prevention and control of PCVAD involve a multifaceted approach, including biosecurity measures, co-infection management, and vaccination. Vaccination remains a key tool, with updated vaccines providing protection against multiple PCV2 genotypes. Emerging technologies, such as nanobody-based ELISAs and biosensors, hold promise for faster and more cost-effective diagnostics. Continued research into new vaccine technologies, alongside ongoing surveillance of PCV2 genetic shifts, is critical for effective long-term control of PCVAD and minimizing its impact on the swine industry.